ClinicalTrials.gg
CompletedNCT04145349Updated Aug 7, 2026Results posted

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

A Phase 1/2 interventional study of Ramucirumab and Cyclophosphamide in Desmoplastic Small Round Cell Tumor, sponsored by Eli Lilly and Company. Completed at 22 sites in 7 countries. Open to participants aged 12 Months to 29 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
12 Months to 29 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Desmoplastic Small Round Cell Tumor with a site in United States — 8 open to participants now, 14 under way, none of them phase 3. Desmoplastic Small Round Cell Tumor · United States.

Enrollment
19th of 37
30 · median 30
Started
2020
with 4 others
Phase 1/2
7 of 43
4 open now
Registered
31st of 43
by date

Among the 43 studies in Desmoplastic Small Round Cell Tumor with a site in United States, this one is the 19th largest by enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2020, is one of 7 in phase 1/2, and was the 31st registered.

Desmoplastic Small Round Cell Tumor

59 studies on the registry are indexed under Desmoplastic Small Round Cell Tumor; 14 are open to participants now.

Browse Desmoplastic Small Round Cell Tumor studies →

Open to participants now

8 of the 43 studies in Desmoplastic Small Round Cell Tumor with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Desmoplastic Small Round Cell Tumor studies recruiting now, 4 (33%) set no upper age limit and 8 (67%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: 12 Months to 29 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Desmoplastic Small Round Cell Tumor with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE master protocol (NCT05999994) which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.

03

Conditions studied

  • Desmoplastic Small Round Cell Tumor

Keywords

  • soft tissue sarcoma
  • adolescents and young adults (AYAs)
  • adolescent
04

Who can participate

Ages eligible
12 Months to 29 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have discontinued all previous treatments for cancer or agents ≥7 days after the last dose or per the type of previous treatment as stated in the protocol and must have recovered from the acute effects to ≤Grade 2 for alopecia and decreased tendon reflex and to ≤Grade 1 for all other effects at the time of enrollment, unless otherwise noted. Consult with the Lilly clinical research physician or scientist for the appropriate length of time prior to the first dose of study treatment.
  • Participants with , recurrent, or refractory DSRCT.
  • Participants must:

    • Have by , Version (RECIST) 1.1.
    • Have received at least one (including and adjuvant chemotherapy). This prior treatment must include approved therapies for which they are eligible, unless the participant is not a suitable candidate for the approved therapy.
    • Not be eligible for surgical resection at time of enrollment.
  • Adequate cardiac function, defined as: Shortening fraction of ≥27% by echocardiogram, or of ≥50% by gated radionuclide study.
  • Adequate blood pressure (BP) control, defined as:

    • Participants ≥18 years: Controlled hypertension defined as systolic BP ≤150 millimeters of mercury (mmHg) or diastolic BP ≤90 mmHg where standard medical management is permitted. Please note that ≥2 serial BP readings should be obtained and averaged to determine baseline BP.
    • Participants \<18 years: A BP ≤95th percentile for age, height, and gender measured as described in National High Blood Pressure Education Program Working Group (NHBPEPWG) on High Blood Pressure in Children and Adolescents (2004), where standard medical management is permitted. Please note that ≥2 serial BP readings should be obtained and averaged to determine baseline BP.
  • Adequate hematologic function, as defined as:

    • (ANC): ≥750/microliters (µL) granulocyte-colony stimulating factor (G-CSF) permitted up to 48 hours prior. Participants with documented history of benign ethnic neutropenia or other conditions could be considered with a lower ANC after discussion with and approval from the Lilly clinical research physician or scientist.
    • : ≥75,000/cubic millimeters. Platelet transfusion permitted up to 72 hours prior.
    • : ≥8 grams per deciliter (g/dL) (≥80 g/liter). Transfusions to increase the participant's hemoglobin level to at least 8 g/dL are permitted; however, study treatment must not begin until 7 days after the transfusion, and complete blood count criteria for eligibility are confirmed within 24 hr of first study dose.
  • Adequate renal function, as defined as:

    • or radioscope (GFR) ≥60 milliliters/minute/meters squared OR serum creatinine meeting the following parameters:

      • for participants ≥18 years of age serum creatinine ≤1.5× (ULN);
      • for participants \<18 years of age, serum creatinine based on age/gender as follows: Age 1 to \<2 years maximum serum creatinine 0.6, Age 2 to \<6 years maximum serum creatinine 0.8, Age 6 to \<10 years maximum serum creatinine 1.0, Age 10 to \<13 years maximum serum creatinine 1.2, Age 13 to \<16 years maximum serum creatinine 1.5 for males and 1.4 for females, Age 16 to \<18 years maximum serum creatinine 1.7 for males and 1.4 for females.
    • Urine protein meeting the following parameters:

      • for participants ≥18 years of age: \<2+ on dipstick or routine urinalysis. If urine dipstick or routine analysis indicates proteinuria ≥2+, then a 24-hour urine must be collected and must demonstrate \<2 grams of protein in 24 hours to allow participation in the study.
      • for participants \<18 years of age: ≤30 milligrams per deciliter urine analysis or \<2+ on dipstick. If urine dipstick or routine analysis indicates proteinuria ≥2+, then a 24-hour urine must be collected and must demonstrate \<1 g of protein in 24 hours to allow participation in the study.
  • Adequate liver function:

    • Total : ≤1.5×ULN. Except participants with document history of Gilbert Syndrome who must have a total bilirubin level of \<3.0×ULN.
    • (ALT) and aspartate aminotransferase (AST): ≤2.5×ULN OR ≤5.0×ULN if the liver has tumor involvement.
  • The participant has an adequate coagulation function as defined by ≤1.5 or prothrombin time ≤1.5×ULN, and partial thromboplastin time ≤1.5×ULN if not receiving anticoagulation therapy. For participants receiving anticoagulants, exceptions to these coagulation parameters are allowed if they are within the intended or expected range for their therapeutic use. Participants must have no history of active bleeding (defined as within 14 days of first dose of study drug) or pathological condition that carries a high risk of bleeding (for example, tumor involving major vessels or known esophageal varices).
  • The participant has adequate hematologic and organ function ≤1 week (7 days) prior to first dose of study drug.
  • Female participants of must have a negative urine or serum pregnancy test within 7 days prior to randomization. Male and female participants must agree to use highly effective for the duration of the study and up to 3 months following the last dose of ramucirumab and vinorelbine, and 12 months following the last dose of cyclophosphamide in order to prevent pregnancy.

Exclusion criteria

Exclusion Criteria:

  • Participants with severe and/or uncontrolled concurrent medical disease or psychiatric illness/social situation that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol.
  • Participants who have active infections requiring therapy.

    • Participants with an active fungal, bacterial, and/or known severe viral infection including, but not limited to, (HIV) or viral (A, B, or C) hepatitis (screening is not required).
  • Participants who have had allogeneic bone marrow or solid organ transplant are excluded.
  • Surgery: Participants who have had, or are planning to have, the following invasive procedures are not eligible:

    • Major surgical procedure, laparoscopic procedure, or significant traumatic injury within 28 days prior to enrollment.
    • Central line placement or subcutaneous port placement is not considered major surgery.
    • Core , fine needle aspirate, and bone marrow biopsy/aspirate are not considered major surgeries.
    • Surgical or other wounds must be adequately healed prior to enrollment.
  • Bleeding and thrombosis:

    • Participants with evidence of active bleeding or a history of significant (≥Grade 3) bleeding event within 3 months prior to enrollment are not eligible.
    • Participants with a bleeding diathesis or vasculitis are not eligible.
    • Participants with known or prior history in the prior 3 months of esophageal varices are not eligible.
    • Participants with a history of deep vein thrombosis requiring medical intervention (including pulmonary embolism) within 3 months prior to study enrollment are not eligible.
    • Participants with a history of hemoptysis or other signs of pulmonary hemorrhage within 3 months prior to study enrollment are not eligible.
  • Cardiac:

    • Participants with a history of central nervous system (CNS) arterial/venous thromboembolic events (VTEs) including (TIA) or cerebrovascular accident (CVA) within 6 months prior to study enrollment are not eligible.
    • Participants with myocardial infarction or unstable angina within the prior 6 months.
    • Participants with Grade 2 or greater congestive heart failure (CHF).
    • Participants with serious and inadequately controlled cardiac arrhythmia.
    • Participants with significant vascular disease (eg, aortic aneurysm, history of aortic dissection).
    • Participants with peripheral vascular disease.
  • Participants who have a history of fistula, gastrointestinal (GI) ulcer or perforation, or intra-abdominal abscess within 3 months of study enrollment are not eligible.
  • Participants with a history of hypertensive crisis or hypertensive encephalopathy within 6 months of study enrollment are not eligible.
  • Participants who have non-healing wound, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrollment are not eligible.
  • Participants previously treated and progressed on combination cyclophosphamide and vinorelbine regimen. Participants who received combination as maintenance therapy, without progression, would be eligible.
  • Participants with a known to ramucirumab, cyclophosphamide, vinorelbine or any of the of the medicinal products.
  • Hepatic impairment:

    • Severe liver cirrhosis Class B (or worse).
    • Cirrhosis with a history of hepatic encephalopathy.
    • Clinically meaningful ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis.
    • History of hepatorenal syndrome.
  • The participant has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection (eg, hemicolectomy or extensive small intestine resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea.
  • The participant has a urinary outflow obstruction.
  • The participant has Grade 2 hematuria or non-infectious cystitis at the time of screening.
  • Participants with central nervous system (CNS) involvement are ineligible.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Ramucirumab + Cyclophosphamide + Vinorelbine

    Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met. * Ramucirumab administered intravenously at a dose of 12 milligrams per kilogram (mg/kg) as a one-hour infusion on days 1 and 15. * Cyclophosphamide administered orally at 25 milligrams per meter square (mg/m2) daily from days 1 to 28. * Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15.

    Drug: Ramucirumab · Drug: Cyclophosphamide · Drug: Vinorelbine

  • Active comparator
    Cyclophosphamide + Vinorelbine

    Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met. * Cyclophosphamide administered orally at 25 mg/m² daily from days 1 to 28. * Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15.

    Drug: Cyclophosphamide · Drug: Vinorelbine

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from randomization to the date of investigator-determined objective progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause in the absence of disease progression. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later). The posterior median and 98% credible interval were estimated using Bayesian analysis. Data are presented as the posterior median with 98% credible interval.

    Time frame: Randomization to Objective Progression or Death Due to Any Cause (Up To 23 Months)

Secondary outcomes

  1. Overall Response Rate (ORR): Percentage of Participants Who Achieved a Complete Response (CR) or Partial Response (PR)

    * The ORR was defined as the percentage of participants achieving either a CR or PR. Tumor response was assessed based on histology: Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) was used for solid tumors, and Response Assessment in Neuro-Oncology criteria were used for glioblastoma. * CR was defined as the disappearance of all target lesions, with any pathological lymph nodes (whether target or non-target) showing a reduction in the short axis to \<10 mm. Tumor marker results were required to have normalized. PR was defined as a decrease of at least 30% in the sum of the diameters of target lesions, using baseline diameters as the reference.

    Time frame: Randomization until measured progressive disease (Up To 23 Months)

  2. Duration of Response (DoR)

    DoR is defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective disease progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence .Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

    Time frame: Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up To 23 Months)

  3. Complete Response (CR) : Percentage of Participants Who Achieved a CR

    CR was defined as the disappearance of all target lesions, with any pathological lymph nodes (whether target or non-target) showing a reduction in the short axis to \<10 mm.Tumor marker results were required to have normalized.

    Time frame: Randomization until measured progressive disease (Up To 23 Months)

  4. Pharmacokinetics (PK): Maximum Serum Concentration of Ramucirumab (Cmax)

    Cmax was the concentration of study drug in the blood after the dose is administered. It was measured post-dose and was summarized using descriptive statistics.

    Time frame: End of ramucirumab infusion on Day 1 of Cycle 1

  5. PK: Minimum Serum Concentration of Ramucirumab (Cmin)

    Cmin was the concentration of study drug in the blood immediately before the next dose was administered. It was measured pre-dose at all visits and was summarized using descriptive statistics.

    Time frame: Prior to ramucirumab infusion on - Day 15 of Cycle 1 and Day 1 of Cycles 2, 4, 7, and 10

  6. Number of Participants With Treatment-Emergent Anti-Drug Antibodies (TE-ADA)

    A TE-ADA evaluable participant is considered TE-ADA positive if they have at least one post-baseline ADA titer that is a 4-fold or greater increase from their baseline titer (treatment-boosted); alternatively, if the baseline ADA result is Not Present, the participant is considered TE-ADA positive if there is at least one post-baseline ADA result that is Present with a titer greater than or equal to 1:20 (treatment-induced).

    Time frame: Baseline Up to 23 months

07

Results

Posted Jul 20, 2025

Participant flow

Participant flow — Overall Study
MilestoneRamucirumab + Cyclophosphamide + VinorelbineCyclophosphamide + Vinorelbine
Started2010
Received at least one dose of study drug2010
Completed127
Not completed83
Withdrew: Withdrawal by subject82
Withdrew: Lost to follow-up01

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS was defined as the time from randomization to the date of investigator-determined objective progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause in the absence of disease progression. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later). The posterior median and 98% credible interval were estimated using Bayesian analysis. Data are presented as the posterior median with 98% credible interval.

Time frame:
Randomization to Objective Progression or Death Due to Any Cause (Up To 23 Months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsRamucirumab + Cyclophosphamide + VinorelbineCyclophosphamide + Vinorelbine
Progression Free Survival (PFS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Ramucirumab + Cyclophosphamide + Vinorelbine vs Cyclophosphamide + Vinorelbine · Bayesian hierarchical model · Posterior mean hazard ratio: 0.69 · 98% CI 0.25 to 1.69
SecondaryOverall Response Rate (ORR): Percentage of Participants Who Achieved a Complete Response (CR) or Partial Response (PR)

* The ORR was defined as the percentage of participants achieving either a CR or PR. Tumor response was assessed based on histology: Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) was used for solid tumors, and Response Assessment in Neuro-Oncology criteria were used for glioblastoma. * CR was defined as the disappearance of all target lesions, with any pathological lymph nodes (whether target or non-target) showing a reduction in the short axis to \<10 mm. Tumor marker results were required to have normalized. PR was defined as a decrease of at least 30% in the sum of the diameters of target lesions, using baseline diameters as the reference.

Time frame:
Randomization until measured progressive disease (Up To 23 Months)
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR): Percentage of Participants Who Achieved a Complete Response (CR) or Partial Response (PR)
Percentage of participantsRamucirumab + Cyclophosphamide + VinorelbineCyclophosphamide + Vinorelbine
Overall Response Rate (ORR): Percentage of Participants Who Achieved a Complete Response (CR) or Partial Response (PR)10 (2.7 to 24.5)10 (1.1 to 33.7)
SecondaryDuration of Response (DoR)

DoR is defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective disease progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence .Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).

Time frame:
Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up To 23 Months)
Reported as:
Median · Months
Duration of Response (DoR)
MonthsRamucirumab + Cyclophosphamide + VinorelbineCyclophosphamide + Vinorelbine
Duration of Response (DoR)9.55 (4.89 to NA)NA (NA to NA)
SecondaryComplete Response (CR) : Percentage of Participants Who Achieved a CR

CR was defined as the disappearance of all target lesions, with any pathological lymph nodes (whether target or non-target) showing a reduction in the short axis to \<10 mm.Tumor marker results were required to have normalized.

Time frame:
Randomization until measured progressive disease (Up To 23 Months)
Reported as:
Number · Percentage of participants
Complete Response (CR) : Percentage of Participants Who Achieved a CR
Percentage of participantsRamucirumab + Cyclophosphamide + VinorelbineCyclophosphamide + Vinorelbine
Complete Response (CR) : Percentage of Participants Who Achieved a CR5.0 (0.5 to 18.1)0 (0.0 to 20.6)
SecondaryPharmacokinetics (PK): Maximum Serum Concentration of Ramucirumab (Cmax)

Cmax was the concentration of study drug in the blood after the dose is administered. It was measured post-dose and was summarized using descriptive statistics.

Time frame:
End of ramucirumab infusion on Day 1 of Cycle 1
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
Pharmacokinetics (PK): Maximum Serum Concentration of Ramucirumab (Cmax)
microgram per milliliter (µg/mL)Ramucirumab + Cyclophosphamide + Vinorelbine
Pharmacokinetics (PK): Maximum Serum Concentration of Ramucirumab (Cmax)238 ± 35
SecondaryPK: Minimum Serum Concentration of Ramucirumab (Cmin)

Cmin was the concentration of study drug in the blood immediately before the next dose was administered. It was measured pre-dose at all visits and was summarized using descriptive statistics.

Time frame:
Prior to ramucirumab infusion on - Day 15 of Cycle 1 and Day 1 of Cycles 2, 4, 7, and 10
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
PK: Minimum Serum Concentration of Ramucirumab (Cmin)
microgram per milliliter (µg/mL)Ramucirumab + Cyclophosphamide + Vinorelbine
Day 15 of Cycle 141.6 ± 57
Day 1 of Cycle 288.7 ± 47
Day 1 of Cycle 4157 ± 37
Day 1 of Cycle 7155 ± 28
Day 1 of Cycle 10NA ± NA
SecondaryNumber of Participants With Treatment-Emergent Anti-Drug Antibodies (TE-ADA)

A TE-ADA evaluable participant is considered TE-ADA positive if they have at least one post-baseline ADA titer that is a 4-fold or greater increase from their baseline titer (treatment-boosted); alternatively, if the baseline ADA result is Not Present, the participant is considered TE-ADA positive if there is at least one post-baseline ADA result that is Present with a titer greater than or equal to 1:20 (treatment-induced).

Time frame:
Baseline Up to 23 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Anti-Drug Antibodies (TE-ADA)
ParticipantsRamucirumab + Cyclophosphamide + VinorelbineCyclophosphamide + Vinorelbine
Number of Participants With Treatment-Emergent Anti-Drug Antibodies (TE-ADA)00

Adverse events

Collected over Baseline Up to 44.33 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab + Cyclophosphamide + Vinorelbine12/20 (60%)6/20 (30%)20/20 (100%)
Cyclophosphamide + Vinorelbine7/10 (70%)3/10 (30%)10/10 (100%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventRamucirumab + Cyclophosphamide + VinorelbineCyclophosphamide + Vinorelbine
Febrile neutropeniaBlood and lymphatic system disorders2/200/10
Small intestinal obstructionGastrointestinal disorders1/201/10
PyrexiaGeneral disorders2/200/10
BacteraemiaInfections and infestations0/201/10
CellulitisInfections and infestations0/201/10
Vascular access complicationInjury, poisoning and procedural complications0/201/10
SyncopeNervous system disorders2/200/10
AscitesGastrointestinal disorders1/200/10
NauseaGastrointestinal disorders1/200/10
Chest painGeneral disorders1/200/10
Most frequent other events
Showing 10 of 135
Most frequent other events
EventRamucirumab + Cyclophosphamide + VinorelbineCyclophosphamide + Vinorelbine
White blood cell count decreasedInvestigations11/206/10
NeutropeniaBlood and lymphatic system disorders11/201/10
Abdominal painGastrointestinal disorders11/202/10
Alanine aminotransferase increasedInvestigations10/202/10
Neutrophil count decreasedInvestigations10/205/10
HeadacheNervous system disorders10/201/10
ProteinuriaRenal and urinary disorders9/200/10
AnaemiaBlood and lymphatic system disorders8/202/10
VomitingGastrointestinal disorders6/204/10
PyrexiaGeneral disorders5/204/10

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Ramucirumab + Cyclophosphamide + VinorelbineCyclophosphamide + VinorelbineTotal
Mean19.6 ± 5.6721.4 ± 5.0620.2 ± 5.45
Sex: Female, Male
Sex: Female, Male(Participants)Ramucirumab + Cyclophosphamide + VinorelbineCyclophosphamide + VinorelbineTotal
Female505
Male151025
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ramucirumab + Cyclophosphamide + VinorelbineCyclophosphamide + VinorelbineTotal
Hispanic or Latino314
Not Hispanic or Latino16824
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ramucirumab + Cyclophosphamide + VinorelbineCyclophosphamide + VinorelbineTotal
American Indian or Alaska Native000
Asian246
Native Hawaiian or Other Pacific Islander000
Black or African American415
White13417
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(Participants)Ramucirumab + Cyclophosphamide + VinorelbineCyclophosphamide + VinorelbineTotal
United States549
Japan134
Italy314
United Kingdom516
Australia101
Germany303
Spain213
08

Study locations

22 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Children's Hospital of Los Angeles
    Los Angeles, California 90027, United States
  • Children's National Medical Center
    Washington D.C., District of Columbia 20010, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Children's Hospital of Philadelphia (CHOP)
    Philadelphia, Pennsylvania 19104, United States
  • Royal Children's Hospital
    Parkville, Victoria 3052, Australia
  • Universitaetsklinikum Freiburg
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Universitaetsklinikum Essen
    Essen, North Rhine-Westphalia 45122, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20251, Germany
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, Lombardy 20133, Italy
  • Humanitas
    Rozzano, Milano 20089, Italy
  • Ospedale Pediatrico Bambino Gesù
    Rome, Roma 165, Italy
  • Azienda Ospedaliera di Padova
    Padova, Veneto 35128, Italy
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
  • Kyushu University Hospital
    Fukuoka, 812-8582, Japan
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
  • University College London Hospital
    London, London, City of NW1 2PG, United Kingdom
  • Royal Marsden Hospital (Sutton)
    London, Sutton SM2 5PT, United Kingdom
  • Royal Manchester Children's Hospital
    Manchester, M13 9WL, United Kingdom
  • The Christie
    Manchester, M20 4BX, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Jun 2024, 52 months.

Results were first posted in Jul 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2019
First posted
Oct 30, 2019
StartActual
Jan 22, 2020
Primary completionActual
Jun 14, 2024
CompletionActual
Jan 23, 2026
Results first posted
Jul 20, 2025
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04145349
Responsible party
Sponsor
First posted
Oct 30, 2019
Start date
Jan 22, 2020
Primary completion
Jun 14, 2024
Completion
Jan 23, 2026
Results posted
Jul 20, 2025
Last update
Aug 7, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion